Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
707 Views
eMediNexus 19 November 2021
Atopic dermatitis (AD) is associated with an increased risk of developing other type 2 inflammatory diseases in the affected individuals. However, there is a lack of real-world evidence based on large US commercially insured pediatric populations.
A recent study published in the Journal of the American Academy of Dermatology assessed the prevalence and incidence of type 2 inflammatory diseases (T2D) in pediatric atopic dermatitis (AD) patients using a large US claims database
Assessment for Prevalence was performed for conjunctivitis, rhinitis, urticaria, asthma, eosinophilic esophagitis and chronic rhinosinusitis/nasal polyps, 12 months post-index date.
Also, the 0-2 years old patients were subjected to the evaluation of the incidence of other type 2 inflammatory diseases post-index.
The observations of the study were as follows-
The study enrolled 244,776 AD and matched non-AD patients.
AD patients demonstrated a higher prevalence and incidence of type 2 inflammatory diseases.
The prevalence was found to be more than 2 fold for asthma, eosinophilic esophagitis, urticaria, and rhinitis, which further increased with AD severity.
Thus it was concluded that there is a greater burden of type 2 inflammatory diseases in pediatric AD patients, so it is crucial to optimize the management of AD and its numerous associated morbidities.
Source: Journal of the American Academy of Dermatology, 2021, https://doi.org/10.1016/j.jaad.2021.10.038.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}